Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Potenza Therapeutics

Pharma deals in September 2015

September saw an interesting mix of deal types and structures, disease areas and companies hitting our Deal Watch radar. Oncology deals continue to be prominent, but the month also saw...

Bristol-Myers Squibb (BMS) building

BMS signs $1.74bn deal to boost immuno-oncology portfolio

Gainsaccess to Five Prime Therapeutics CSF1R antibody programme

- PMLiVE

Novartis signs $500m immuno-oncology deal

Gains access to Xoma's TGFb antibody programme

- PMLiVE

Astellas selects new CFO for its EMEA operations

Japanesefirm also appoints newmanager for its US corporate affairs team

Pharma deals in August 2015

During a busy month AstraZeneca, Sanofi and Shire were among those hitting the headlines

- PMLiVE

Astellas launches cancer challenge social media campaign

Teamsup with USA Rugby and the Australian Rugby Union for #pass4prostate

- PMLiVE

J&J buys into Alligator’s immuno-oncology candidate

Will spend $700m on the early-stage cancer deal

- PMLiVE

AZ adds cancer vaccine to immuno-oncology portfolio

Firm's biologics unit adds to string of oncology deals in 2015

Sanofi reception

Sanofi and Evotec to work together on diabetes and cancer

Willfocus on beta cell-modulating diabetes treatments and immuno-oncology therapies

- PMLiVE

AZ signs two more deals in cancer immunotherapy

Anglo-Swedish firm pens partnerships with Heptares and Mirati Therapeutics

Pharma deals in July 2015

A hot summer month for industry M&A, finds Medius Deal Watch

Pharma deals in June 2015

Allergan's $2.1bn acquisition of Kythera tops this month's deals

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links